Zentalis Pharmaceuticals reported that Chief Executive Officer Julia Marie Eastland sold a total of 8,755 shares of the company's common stock on February 6 and February 9, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The filing shows the aggregate value of the transactions was $21,239, with execution prices ranging from $2.3929 to $2.4297 per share. On February 6, Eastland sold 7,866 shares, and on February 9 she sold a further 889 shares.
The Form 4 specifies that the sales were automatic transactions carried out by Zentalis Pharmaceuticals to satisfy tax withholding obligations that arose upon the vesting and settlement of restricted stock units previously granted to Eastland.
Following these automated sales, Eastland's direct holdings in Zentalis Pharmaceuticals stand at 79,133 shares, as listed in the filing.
Separately, Zentalis has updated investors on its development portfolio. The company disclosed it will discontinue the active development of its azenosertib candidate for uterine serous carcinoma. That announcement was made in conjunction with Zentalis's third-quarter 2025 earnings report and a broader pipeline update.
In response to the clinical program change and the accompanying corporate update, Leerink Partners reduced its price target for Zentalis from $5.00 to $2.00. The research firm, however, retained a Market Perform rating on the stock.
These disclosures - the CEO's automatic sales to cover tax liabilities and the decision to halt active development of azenosertib - were both captured in regulatory filings and company public statements provided with the earnings and pipeline report.
The sequence of events highlights recent adjustments in Zentalis's strategic priorities and has led at least one analyst to revise expectations for the equity. The Form 4 filing documents the mechanics and purpose of the insider sales, while the company update and analyst action reflect recent changes to the firm's clinical and valuation outlook.